Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
14 04 2021
Historique:
received: 21 08 2020
accepted: 09 03 2021
entrez: 15 4 2021
pubmed: 16 4 2021
medline: 12 5 2021
Statut: epublish

Résumé

Breast cancer is a heterogeneous disease, affecting over 3.5 million women worldwide, yet the functional role of cis-regulatory elements including super-enhancers in different breast cancer subtypes remains poorly characterized. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis. Here we apply integrated epigenomic and transcriptomic profiling to uncover super-enhancer heterogeneity between breast cancer subtypes, and provide clinically relevant biological insights towards TNBC. Using CRISPR/Cas9-mediated gene editing, we identify genes that are specifically regulated by TNBC-specific super-enhancers, including FOXC1 and MET, thereby unveiling a mechanism for specific overexpression of the key oncogenes in TNBC. We also identify ANLN as a TNBC-specific gene regulated by super-enhancer. Our studies reveal a TNBC-specific epigenomic landscape, contributing to the dysregulated oncogene expression in breast tumorigenesis.

Identifiants

pubmed: 33854062
doi: 10.1038/s41467-021-22445-0
pii: 10.1038/s41467-021-22445-0
pmc: PMC8046763
doi:

Substances chimiques

ANLN protein, human 0
FOXC1 protein, human 0
Forkhead Transcription Factors 0
Microfilament Proteins 0
MET protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-met EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2242

Références

Mol Cell. 2017 Apr 20;66(2):285-299.e5
pubmed: 28416141
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
NPJ Breast Cancer. 2016 Jul 13;2:16022
pubmed: 28721382
Nat Methods. 2012 Feb 28;9(3):215-6
pubmed: 22373907
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Commun. 2016 Sep 28;7:12983
pubmed: 27677335
Science. 2014 Dec 12;346(6215):1373-7
pubmed: 25394790
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
Genome Res. 2017 Feb;27(2):259-268
pubmed: 27965291
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21931-6
pubmed: 21106759
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Nature. 2016 Jan 21;529(7586):413-417
pubmed: 26735014
Aging (Albany NY). 2018 Aug 09;10(8):1884-1901
pubmed: 30103211
Differentiation. 2010 Jan;79(1):31-40
pubmed: 19782461
Nat Genet. 2014 Feb;46(2):136-143
pubmed: 24413736
Nat Genet. 2017 Aug;49(8):1261-1266
pubmed: 28650485
Nat Genet. 2016 Jan;48(1):12-21
pubmed: 26618344
BMC Bioinformatics. 2006 Mar 20;7 Suppl 1:S7
pubmed: 16723010
Semin Cell Dev Biol. 2010 Dec;21(9):881-91
pubmed: 20732437
Mol Cell Biochem. 2015 Jan;398(1-2):11-9
pubmed: 25223638
Cancer Sci. 2018 Dec;109(12):3794-3804
pubmed: 30290049
Cancer Discov. 2017 Aug;7(8):884-899
pubmed: 28446439
BMC Genomics. 2018 Feb 20;19(1):150
pubmed: 29458327
Gastroenterology. 2015 Oct;149(4):1053-67.e14
pubmed: 26065367
J Cell Biol. 2000 Aug 7;150(3):539-52
pubmed: 10931866
Nucleic Acids Res. 2020 Jan 8;48(D1):D87-D92
pubmed: 31701148
Bioinformatics. 2011 Mar 15;27(6):879-80
pubmed: 21258062
Clin Cancer Res. 2009 Sep 15;15(18):5714-23
pubmed: 19723643
Cancer Res. 2010 May 15;70(10):3870-6
pubmed: 20406990
Methods. 2003 Jul;30(3):256-68
pubmed: 12798140
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Exp Mol Med. 2020 May;52(5):713-723
pubmed: 32382065
Nat Commun. 2018 Mar 5;9(1):943
pubmed: 29507293
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
BMC Cancer. 2016 Nov 18;16(1):904
pubmed: 27863473
J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6
pubmed: 10904098
Nat Med. 2014 Oct;20(10):1130-7
pubmed: 25194570
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Oncogene. 2012 Aug 9;31(32):3667-78
pubmed: 22120723
Cell. 2015 Sep 24;163(1):174-86
pubmed: 26406377
Genome Res. 2018 Feb;28(2):159-170
pubmed: 29273624
Cell Commun Signal. 2017 Jun 19;15(1):22
pubmed: 28629477
Mol Cell. 2015 Apr 16;58(2):362-70
pubmed: 25801169
Nat Genet. 2016 Feb;48(2):176-82
pubmed: 26656844
Cancer Res. 2005 Dec 15;65(24):11314-25
pubmed: 16357138
Theranostics. 2017 Mar 5;7(5):1177-1191
pubmed: 28435457
Breast Cancer Res. 2020 Jan 7;22(1):3
pubmed: 31910867
Nat Commun. 2014 Jul 10;5:4361
pubmed: 25008978
Genome Biol. 2012 Oct 03;13(10):R87
pubmed: 23034086
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Nature. 2016 Feb 4;530(7588):57-62
pubmed: 26814967
Nat Commun. 2013;4:2464
pubmed: 24043118
Clin Epigenetics. 2019 Mar 12;11(1):48
pubmed: 30867030
Oncogene. 2018 Mar;37(10):1399-1408
pubmed: 29249801
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W187-91
pubmed: 24799436
J Cell Biochem. 2016 Jul;117(7):1707-17
pubmed: 26666591
Nucleic Acids Res. 2002 Apr 1;30(7):1575-84
pubmed: 11917018
PLoS One. 2020 Jun 25;15(6):e0235343
pubmed: 32584896
Nat Commun. 2017 Apr 05;8:14802
pubmed: 28378740
Bioinformatics. 2011 Jun 1;27(11):1571-2
pubmed: 21493656
Oncogene. 2012 Nov 8;31(45):4798-802
pubmed: 22249250
Science. 2012 May 11;336(6082):736-9
pubmed: 22499810
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
pubmed: 19458158
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166

Auteurs

Hao Huang (H)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.

Jianyang Hu (J)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China.

Alishba Maryam (A)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.

Qinghua Huang (Q)

Department of Breast Surgery, The Affiliate Tumor Hospital, Guangxi Medical University, Nanning, China.

Yuchen Zhang (Y)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.

Saravanan Ramakrishnan (S)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.

Jingyu Li (J)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China.

Haiying Ma (H)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China.

Victor W S Ma (VWS)

Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.

Wah Cheuk (W)

Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong.

Grace Y K So (GYK)

Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong.

Wei Wang (W)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.

William C S Cho (WCS)

Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.

Liang Zhang (L)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China.

Kui Ming Chan (KM)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China.

Xin Wang (X)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong. xin.wang@cityu.edu.hk.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China. xin.wang@cityu.edu.hk.

Y Rebecca Chin (YR)

Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong. rebecca.chin@cityu.edu.hk.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China. rebecca.chin@cityu.edu.hk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH